Peter Mark Richman, who frequently played villains, dies

Peter Mark Richman in an episode of The FBI

Peter Mark Richman, a character actor who had a long career and often played villains, has died at 93, Variety reported.

He was often tapped by QM Productions for its various shows and was part of the “QM Players” of actors frequently employed by producer Quinn Martin.

Richman’s QM credits included The FBI (appearing as a guest star in eight of nine seasons), The Invaders, The Fugitive, Cannon, Barnaby Jones, and The Streets of San Francisco. The actor was part of a big cast for the QM TV movie House on Greenapple Road, which led to the Dan August series.

Richman also was called upon by casting directors for 1960s spy shows, including The Wild Wild West, The Man From U.N.C.L.E. (the show’s two-part series finale), It Takes a Thief, and Mission: Impossible.

He also was the lead in Agent for H.A.R.M. (1966), which mixed spy fi with sci fi. The cast also included Aliza Gur, who earlier appeared in From Russia With Love as one of the two gypsy fighting women.

The production was poked fun at on Mystery Science 3000, where a host and two puppets (which were supposed to be robots) provided running commentary.

Richman’s IMDB.COM ENTRY lists more than 150 credits from 1953 to 2016.

UPDATE: The Silver Age Television account on Twitter embedded a clip where Richman appears. It’s pretty typical of the characters that Richman played.

RIP #PeterMarkRichman pic.twitter.com/gxWiybAzt0

— Silver Age Television 📺 (@SilverAgeTV) January 15, 2021

Bond 26 and beyond

Image for the official James Bond feed on Twitter

Bond fans are waiting for another delay for the release of No Time to Die/Bond 25. If/when (probably when) that happens, the bigger question is for Bond 26 and beyond.

No Time to Die was a pre-COVID-19 movie with pre-COVID-19 finances. The 25th James Bond film ran up costs approaching $290 million as of mid-2020, according to a U.K, regulatory filing.

But, hey, it was a contender for a theatrical box office of $1 billion or more (split with theaters). Certainly Metro-Goldwyn-Mayer (Bond’s home studio) and Danjaq LLC (parent company of Eon Productions) were working on that assumption.

Then, of course, COVID-19 changed everything. Theaters were shut down in many regions. And the virus — despite the emergence of vaccines — has not been brought to heel. At least not yet and maybe not soon.

Perhaps you can just kick the can. Delay the release date one, two, who knows how many times? Eventually, everything will be back to normal.

Won’t it?

No Time to Die is on the shelf. It will get shown. Sometime.

The big question is what happens with Bond 26, whenever that gets made, and in whatever form.

Studios such as Walt Disney Co. and AT&T’s Warner Bros. have embraced the streaming model model. MGM reportedly shopped No Time to Die around for a streaming deal but couldn’t get the price it wanted.

What’s more, MGM reportedly has put itself up for sale. The studio’s association with Bond will reach its 40th anniversary this year. The Bond-MGM association has been a rocky one, dysfunctional even.

Danjaq/Eon controls the rights to Bond. But Danjaq/Eon needs MGM (whether by itself or in alliance with other studios) to get 007 movies made.

Put another way, there are a lot of issues that need to be addressed before you can even talk about future Bond adventures.

Example: Is the traditional model of a big theatrical release followed by home video revenues even practical now? Or do studios need to reduce the costs of big “tentpole” films?

Of major tentpoles, Bond seemingly is in a good position to ramp down and do more cost-effective productions. The early 007 films such as Dr. No, From Russia With Love and Goldfinger, were pretty lean films.

Still, that was almost 60 years ago. Things change.

No Time to Die may be a rousing James Bond film. But Bond’s future still is being determined — and things are more uncertain than James Bond emerging triumphant at the end of a movie.